Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Salvage and Consolidation in Relapsed Large B-cell Lymphoma
NCT06287398Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Australasian Leukaemia & Lymphoma Group. Started Dec 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06287398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287398.